Dr. Abbey Presents ARCHER II Clinical Trial Data at The Retina Society Annual Scientific Meeting
Texas Retina’s Ashkan Abbey, MD, presented baseline characteristics of participants in the Phase 3 ARCHER II clinical trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) at the 59th
read more
Texas Retina Dallas Research Team Recognized for Highest Site Enrollment Globally in Geographic Atrophy Clinical Trial
Under the leadership of Principal Investigator Dr. Ashkan M. Abbey, the Texas Retina Dallas research team was recently named the top enroller for Part I of the DFI18231 study, which is evaluating
read more
New Clinical Trials Available at Texas Retina
At Texas Retina, we remain committed to conducting ongoing research that will advance retinal care. That is why for over 20 years, for physicians have participated in more than 100 national clinical
read more
Dr. Abbey Presents GALE Study Data at the Association for Research in Vision and Ophthalmology
At this year’s ARVO 2024, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Texas Retina’s Dr. Abbey presented 36-month data from the GALE study of pegcetacoplan (brand
read more
Texas Retina Associates First in U.S. to Dose a Patient in the Phase 2 SIGLEC Trial
On June 1, 2023, Ashkan Abbey, MD, dosed the first patient in the Phase II SIGLEC Trial, a clinical study evaluating AVD-104, a potential new treatment for geographic atrophy (GA) from age-related
read more